Huang Can, Liu Xiaolin, Wang Weimo, Guo Zhen
Hunan Key Laboratory of the Fundamental and Clinical Research on Functional Nucleic Acid, Changsha Medical University, Changsha, 410219, China.
Hunan Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha, 410219, China.
Curr Comput Aided Drug Des. 2024 Oct 14. doi: 10.2174/0115734099305631240930054417.
Centipeda minima (CM) is a traditional Chinese herbal medicine used for the treatment of sinusitis and rhinitis, and it possesses anti-cancer properties. However, the mechanism of CM in the treatment of nasopharyngeal carcinoma (NPC) remains unclear.
This study aimed to explore the mechanism of CM in the treatment of NPC using a network pharmacology approach.
The active components and targets of CM and NPC were screened using TCMSP, SwissTarget, and GeneCards database. The association between CM components and NPC targets or pathways was analyzed using String, Cytoscape 3.9.1, David 6.7, and AutoDock Vina. The Sangerbox platform was used to conduct differential expression and Kaplan-Meier survival analysis of core genes.
We identified 17 active compounds of CM and 146 corresponding targeted proteins in NPC. These targets may modulate pathways in cancer, PI3K-Akt, apoptosis, prolactin, relaxin, and TNF signaling. The top 5 core genes of the PPI network were found to be AKT1, STAT3, CASP3, EGFR, and SRC, which may be the main targets of CM in treating NPC. Molecular docking confirmed the binding energies of quercetin with CASP3, 8-Hydroxy-9,10-diisobutyryloxythymol with AKT1, and plenolin with AKT1, which were particularly low, suggesting robust and stable interactions. The expression levels of AKT1, CASP3, EGFR, SRC, MMP9, CCND1, and PTGS2 were significantly higher in head and neck squamous cell carcinoma (HNSC) samples compared to normal samples. In addition, the hub genes could predict the prognosis of HNSC as the Kaplan-Meier survival curve showed that patients with lower expressions of AKT1, STAT3, CASP3, EGFR, MMP9, ESR1, PTGS2, and PPARG had better overall survival.
By conducting a network pharmacology approach, we revealed the main ingredients, key targets, and regulatory pathways of Centipeda minima in the treatment of NPC.
鹅不食草是一种用于治疗鼻窦炎和鼻炎的传统中草药,且具有抗癌特性。然而,鹅不食草治疗鼻咽癌(NPC)的机制仍不清楚。
本研究旨在采用网络药理学方法探索鹅不食草治疗NPC的机制。
利用中药系统药理学数据库与分析平台(TCMSP)、SwissTarget和基因卡片数据库筛选鹅不食草和NPC的活性成分及靶点。使用String、Cytoscape 3.9.1、David 6.7和AutoDock Vina分析鹅不食草成分与NPC靶点或通路之间的关联。利用Sangerbox平台对核心基因进行差异表达和Kaplan-Meier生存分析。
我们鉴定出鹅不食草的17种活性化合物以及NPC中146种相应的靶向蛋白。这些靶点可能调节癌症、PI3K-Akt、凋亡、催乳素、松弛素和TNF信号通路。蛋白质-蛋白质相互作用(PPI)网络的前5个核心基因被发现是AKT1、信号转导和转录激活因子3(STAT3)、半胱天冬酶3(CASP3)、表皮生长因子受体(EGFR)和原癌基因酪氨酸蛋白激酶(SRC),它们可能是鹅不食草治疗NPC的主要靶点。分子对接证实槲皮素与CASP3、8-羟基-9,10-二异丁酰氧基百里香酚与AKT1、蛇床子素与AKT1的结合能特别低,表明相互作用强且稳定。与正常样本相比,头颈部鳞状细胞癌(HNSC)样本中AKT1、CASP3、EGFR、SRC、基质金属蛋白酶9(MMP9)、细胞周期蛋白D1(CCND1)和前列腺素内过氧化物合酶2(PTGS2)的表达水平显著更高。此外,枢纽基因可预测HNSC的预后,因为Kaplan-Meier生存曲线显示,AKT1、STAT3、CASP3、EGFR、MMP9、雌激素受体1(ESR1)、PTGS2和过氧化物酶体增殖物激活受体γ(PPARG)表达较低的患者总生存期更好。
通过网络药理学方法,我们揭示了鹅不食草治疗NPC的主要成分、关键靶点和调控通路。